Evaluating new methods for staging and prognosis in malignant pleural mesothelioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates a novel approach to determine the stage and prognosis of patients with malignant pleural mesothelioma. By collecting pleural biopsies during routine diagnostic procedures, the study aims to analyze tissue characteristics that could enhance the accuracy of cancer staging and prognosis estimation prior to surgical intervention. The goal is to improve clinical decision-making and patient outcomes through better classification of cancer severity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All adult patients with a diagnosis of malignant pleural mesothelioma undergoing

  * diagnostic pleural biopsy
  * pleuroscopy
  * and/or VATS resections
* Participants must be 18 years of age or older.

Exclusion Criteria:

-Any patient who is found to be unsuitable for

* surgery,
* treatment
* diagnosis,

Where it's running

• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Raphael Bueno, MD — Brigham and Women's Hospital
• Study coordinator: Raphael Bueno, MD
• Email: rbueno@partners.org
• Phone: 617-732-5690

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Partial pleurectomy to relieve symptoms from unresectable pleural mesothelioma.

  The team will try a limited partial pleurectomy and decortication to reduce chest symptoms and improve quality of life for people with epithelioid pleural mesothelioma that cannot be completely removed.

  Recruiting University of Chicago · Chicago, Illinois · NCT07126509

• Treatment with Sacituzumab Govitecan for Mesothelioma

  This study tests if a new treatment called sacituzumab govitecan can help people with mesothelioma who have already tried other therapies feel better and manage their disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06477419

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Two-part Phase 1/2 test of ODM-212 combined with other cancer treatments

  This trial tests the oral drug ODM-212, given alone or with approved medicines, to see if it helps adults with advanced mesothelioma, pancreatic cancer, or non-small cell lung cancer.

  Recruiting at 23 sites Phase 1/2 Orion Corporation, Orion Pharma · Los Angeles, California and 22 other locations · NCT07563738

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.